KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Deferred Taxes (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Deferred Taxes for 17 consecutive years, with -$392.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 50.44% to -$392.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$965.0 million, a 53.81% increase, with the full-year FY2025 number at -$965.0 million, up 53.81% from a year prior.
  • Deferred Taxes was -$392.0 million for Q4 2025 at Bristol Myers Squibb, down from -$359.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $223.0 million in Q1 2025 to a low of -$1.3 billion in Q4 2023.
  • A 5-year average of -$523.6 million and a median of -$492.5 million in 2023 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: surged 228.3% in 2021, then tumbled 1915.62% in 2022.
  • Bristol Myers Squibb's Deferred Taxes stood at -$1.3 billion in 2021, then soared by 50.71% to -$624.0 million in 2022, then tumbled by 112.66% to -$1.3 billion in 2023, then skyrocketed by 40.39% to -$791.0 million in 2024, then soared by 50.44% to -$392.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Deferred Taxes are -$392.0 million (Q4 2025), -$359.0 million (Q3 2025), and -$437.0 million (Q2 2025).